Jivi - opinion on variation to marketing authorisation

Opinion

EMA has issued an opinion on a change to this medicine's authorisation

damoctocog alfa pegol

Opinion

On 23 July 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Jivi. The marketing authorisation holder for this medicinal product is Bayer AG.

The CHMP adopted an extension to the existing indication as follows:

Treatment and prophylaxis of bleeding in previously treated patients ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency).

For information, the full indication for Jivi will now be:

Treatment and prophylaxis of bleeding in patients ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency).

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

---

Note: Deleted text in strikethrough.

CHMP post-authorisation summary of positive opinion for Jivi (VR/0000326847)

Adopted Reference Number: EMA/542815/2011

Key facts

• Name of medicine:
  Jivi
• EMA product number:
  EMEA/H/C/004054
• Active substance:
  Damoctocog alfa pegol
• International non-proprietary name (INN) or common name:
  damoctocog alfa pegol
• Therapeutic area (MeSH):
  Hemophilia A
• Anatomical therapeutical chemical (ATC) code:
  B02BD02
• Marketing authorisation holder:
  Bayer AG
• Date of opinion:
  23/07/2026
• Status:
  Positive